Stocks
Heron Therapeutics (HRTX) EBITDA margin US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -249.3% | -164.1% | -81.7% | -3.50% | -11.5% | -13.6% | ||
| Changes by years, y/y, % | +2pp | +85pp | +82pp | +78pp | -8pp | -46.0% | |||
Heron Therapeutics. EBITDA margin, %
Heron Therapeutics. EBITDA margin, changes, pp
Heron Therapeutics (HRTX) EBITDA margin US GAAP (quarter values) |
||||||||
| FY2025Q1 | FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | 9.52% | -4.76% | -36.6% | -1.95% | -23.4% | -13.6% | |
| Changes by years, y/y, % | +21pp | +11pp | -25pp | -23pp | -33pp | |||
| Changes by quarters, q/q, % | -12pp | -14pp | -32pp | +35pp | -21pp | |||
